The UK list of medicines that cannot be exported or hoarded is one of the clearest reminders that pharmaceutical wholesale is not just a purchasing exercise. It is a regulated supply-chain responsibility. The Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency updated the list on 10 July 2026, following earlier 2026 changes in January, March and July.
The official guidance states that the list covers medicines that cannot be exported from the UK or hoarded because they are needed for UK patients. The page is updated regularly, so a decision made from an old spreadsheet, historic supplier note or previous order pattern may no longer be safe.
What changed in the July 2026 update?
The 10 July 2026 update removed glucagon and terbutaline presentations from the restricted list. A separate 2 July update added cyclophosphamide powder for solution for injection vials. Earlier in 2026, the page also recorded changes involving rivastigmine patches, dinoprostone, co-codamol, aspirin and ifosfamide.
The practical point is not only which product moved on which date. It is that the restricted list can change several times in a year, and sometimes several times in a month. Wholesale teams should therefore treat the current official list as a control point before accepting, reserving or dispatching stock for export.
Why this matters for WDA holders
The GOV.UK guidance says that hoarding or exporting a medicine on the list is considered a breach of regulation 43(2) of the Human Medicines Regulations 2012 and a contravention of the wholesale dealer licence. The page also notes that regulatory action by the MHRA could include immediate suspension of the wholesale dealer licence.
That makes the restricted medicines list a board-level and responsible-person issue, not a purely operational detail. The same commercial opportunity can look different once the team considers current restrictions, stock allocation, licence conditions and documentary evidence.
A simple operating rhythm for export checks
For wholesalers, brokers and pharmacy groups, a safer export workflow should include:
- checking the current GOV.UK list before accepting an export order;
- recording the date and source used for the check;
- separating UK patient supply commitments from any export discussions;
- escalating restricted or uncertain items to the responsible person;
- keeping evidence of supplier, customer and batch traceability;
- reviewing recurring product categories where restrictions have moved during the year.
These steps do not replace legal or regulatory advice, but they help teams avoid relying on memory when the official list changes.
What partners should ask before sourcing
Before placing demand on a UK supplier, buyers should be clear about the intended market, patient need, requested quantity, order timing and any product-specific documentation requirements. If a medicine is restricted, the correct next step is not to route around the control. It is to reassess the request, confirm the current position and decide whether the order is appropriate.
Logan Pharmaceuticals works in a regulated wholesale context, so export conversations should start with product status, documentation and compliant supply routes. For a product enquiry, contact the team through the Logan contact page and include enough detail for a responsible review.
Sources
Primary source: DHSC and MHRA: Medicines that you cannot export from the UK or hoard, accessed 30 July 2026.